These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24247117)

  • 1. Childhood antineutrophil cytoplasmic antibodies associated vasculitides.
    Twilt M; Benseler S
    Curr Opin Rheumatol; 2014 Jan; 26(1):50-5. PubMed ID: 24247117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis.
    Rich EN; Brown KK
    Curr Opin Pulm Med; 2012 Sep; 18(5):447-54. PubMed ID: 22854508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Uptodate in the management and treatment of ANCA-associated vasculitis].
    Belaconi IN; Toma CL; Bogdan MA
    Pneumologia; 2014; 63(2):78-80, 83-6. PubMed ID: 25241554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evolving treatment of ANCA-associated vasculitides.
    Sauranen J; Salmela A; Kahlos K; Antonen J; Ekstrand A; Pettersson T
    Duodecim; 2016; 132(16):1449-55. PubMed ID: 29188932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance of Remission in antineutrophil cytoplasm antibody-associated vasculitides.
    Guillevin L; Terrier B
    Int J Rheum Dis; 2019 Jan; 22 Suppl 1():100-104. PubMed ID: 29673090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis.
    Rutgers A; Kallenberg CG
    Curr Opin Rheumatol; 2012 May; 24(3):245-51. PubMed ID: 22410545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
    Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X
    Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ANCA-associated vasculitides: advances in pathophysiology and treatment.
    Erwig LP; Savage CO
    Neth J Med; 2010 Feb; 68(2):62-7. PubMed ID: 20167957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasculitis: clinical approach, pathophysiology and treatment.
    Kallenberg CG
    Wien Klin Wochenschr; 2000 Aug; 112(15-16):656-9. PubMed ID: 11020951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ANCA vasculitis: time for a change in treatment paradigm? Not yet.
    Ntatsaki E; Mooney J; Watts RA
    Rheumatology (Oxford); 2011 Jun; 50(6):1019-24. PubMed ID: 21292735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term patient survival in ANCA-associated vasculitis.
    Flossmann O; Berden A; de Groot K; Hagen C; Harper L; Heijl C; Höglund P; Jayne D; Luqmani R; Mahr A; Mukhtyar C; Pusey C; Rasmussen N; Stegeman C; Walsh M; Westman K;
    Ann Rheum Dis; 2011 Mar; 70(3):488-94. PubMed ID: 21109517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in ANCA-associated disease.
    Falk RJ; Jennette JC
    N Engl J Med; 2010 Jul; 363(3):285-6. PubMed ID: 20647204
    [No Abstract]   [Full Text] [Related]  

  • 13. [Maintainance treatment of anti-neutrophil cytoplasm associated antibodies (ANCA)].
    Dábague Guzmán J; Pedroza Granados J; Zúñiga Varga J
    Reumatol Clin; 2011 Dec; 7 Suppl 3():S37-40. PubMed ID: 22119277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antineutrophil cytoplasmic antibody-associated vasculitides.
    Seo P; Stone JH
    Am J Med; 2004 Jul; 117(1):39-50. PubMed ID: 15210387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of methotrexate in ANCA-associated vasculitides.
    Reinhold-Keller E; de Groot K
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S178-82. PubMed ID: 21044456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Issues associated with the Ministry of Health, Labour and Welfare diagnostic criteria for antineutrophil cytoplasmic antibody-associated vasculitides: Reclassification of patients in the prospective cohort study of Remission Induction Therapy in Japanese patients with ANCA-associated vasculitides according to the MHLW criteria.
    Sada KE; Yamamura M; Harigai M; Fujii T; Arimura Y; Makino H;
    Mod Rheumatol; 2015 Jul; 25(4):657-9. PubMed ID: 25496407
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent advances to achieve remission induction in antineutrophil cytoplasmic antibody-associated vasculitis.
    Harper L
    Curr Opin Rheumatol; 2010 Jan; 22(1):37-42. PubMed ID: 19770660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Review article: Antineutrophil cytoplasmic antibody in small vessel vasculitis].
    Nakano H; Ozaki S
    Rinsho Byori; 2010 May; 58(5):480-9. PubMed ID: 20560457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre.
    Pullerits R; Ljevak M; Vikgren J; Bokarewa M
    Scand J Immunol; 2012 Oct; 76(4):411-20. PubMed ID: 22823472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-influenza vaccination vasculitides: a possible new entity.
    Zafrir Y; Agmon-Levin N; Shoenfeld Y
    J Clin Rheumatol; 2009 Sep; 15(6):269-70. PubMed ID: 19734729
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.